Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors

被引:0
作者
Chunling Zeng
Li Zhu
Xiaona Jia
Yuzhi Pang
Zhang Li
Xiaojing Lu
Feifei Xie
Lili Duan
Yuexiang Wang
机构
[1] Institutes for Translational Medicine (CAS-SMMU),CAS Key Laboratory of Tissue Microenvironment and Tumor, SINH
[2] Changzheng Hospital,Changzheng Hospital Joint Center for Translational Medicine
[3] Shanghai Institute of Nutrition and Health,Department of General Surgery
[4] University of Chinese Academy of Sciences,undefined
[5] Chinese Academy of Sciences,undefined
[6] PLA General Hospital,undefined
[7] Chia Tai Tianqing Pharmaceutical Group Co. Ltd,undefined
来源
Gastric Cancer | 2020年 / 23卷
关键词
Dasatinib; Gastrointestinal stromal tumors (GIST); KIT; Sarcoma; Imatinib resistance;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:837 / 847
页数:10
相关论文
共 201 条
[1]  
Corless CL(2011)Gastrointestinal stromal tumours: origin and molecular oncology Nat Rev Cancer 11 865-878
[2]  
Barnett CM(2018)Molecular characterization and pathogenesis of gastrointestinal stromal tumor Transl Gastroenterol Hepatol 3 2-580
[3]  
Heinrich MC(1998)Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577-1491
[4]  
Niinuma T(2010)Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size Am J Surg Pathol 34 1480-1989
[5]  
Suzuki H(2014)Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors Expert Opin Pharmacother. 15 1979-480
[6]  
Sugai T(2002)Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472-38
[7]  
Hirota S(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet. 368 1329-302
[8]  
Isozaki K(2013)Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet. 381 295-58
[9]  
Moriyama Y(2012)The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy Annu Rev Med. 63 247-S41
[10]  
Hashimoto K(2010)NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors J Natl Compr Canc Netw. 8 S1-62